100 Bayer Road
It all starts with a friendship between two men, plenty of natural curiosity and two kitchen stoves. Businessman Friedrich Bayer and dyer Johann Friedrich Weskott use these to conduct experiments and eventually discover how to make the dye fuchsine.
On August 1, 1863, they found the "Friedr. Bayer et. comp." company in Wuppertal-Barmen, a 19th century startup with tremendous potential.
Bayer is a Life Science company with a more than 150-year history and core competencies in the areas of health care and agriculture. With our innovative products, we are contributing to finding solutions to some of the major challenges of our time.
Our goal is to create value for our customers, stockholders and employees, while also strengthening the company’s earning power. We are committed to operating sustainably and addressing our social and ethical responsibilities. Employees with a passion for innovation enjoy excellent development opportunities at Bayer.
All this goes to make up our purpose: Science for a better life.
Passion to innovate | Power to change
500 articles with Bayer
Bayer released the following statement in reaction to a phase one verdict in favor of the plaintiff in the case of Hardeman v Monsanto, a trial conducted in the federal glyphosate multi-district litigation before Judge Vince Chhabria in the Northern District of California.
No one should start, stop or modify an aspirin regimen without first speaking with their healthcare provider.
Bayer's Phase III Clinical Trial Of Nifurtimox In Pediatric Patients With Chagas Disease Meets Primary Endpoint
Bayer presented results today from the CHICO part (CHagas disease In Children treated with NifurtimOx) of the phase III clinical study of investigational nifurtimox in pediatric patients with Chagas disease at the "XV Taller sobre la enfermedad de Chagas" conference in Barcelona, Spain.
The Climate Corporation and NAU Country Insurance Company Partner to Enable Seamless Crop Insurance Reporting for U.S. Farmers
The Climate Corporation, a subsidiary of Bayer, announced a platform agreement between the company's industry-leading Climate FieldView™ digital agriculture platform and NAU Country Insurance Company, a QBE Insurance Company.
Evotec Receives Milestone Payment For Start Of Second Phase Ii Trial In Its Multi-target Alliance With Bayer
Evotec AG announced that another promising small molecule from its multi-target alliance with Bayer has advanced into Phase II clinical development for the treatment of persistent chronic cough.
Could a product in a weed killer contribute to the development of a cancer? That is the question a jury will answer as Bayer faces accusations that glyphosate, the active ingredient in its top=selling weed killer Roundup, caused cancer in some individuals who have used the product.
BioSpace gathered together a roundup of global biopharma news from the past week. Bayer and Orion Corporation, Themis Bioscience, Axonics Modulation Technologies, and more are mentioned in this edition.
Bayer completes rolling submission of New Drug Application to U.S. Food and Drug Administration for investigational drug darolutamide for the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC)
Bayer announced the completion of the rolling submission of a New Drug Application to the U.S. Food and Drug Administration for the investigational drug darolutamide.
"Wall Smashing" Ceremony Initiates Construction Of Bayer Funded Geospatial Innovation And Resource Center at T-REX Business Incubator
"Geosaurus, Powered by Bayer" Will Support Start-Ups and Workforce Programs Focused on Geospatial Technology
If you’re in the pharma or biotech industry and are looking for work, multiple companies have announced expansions of their employee pool over the past few days. BioSpace rounds up a few of the announcements.
As the American Society of Clinical Oncology 2019 Genitourinary Cancers Symposium (ASCO GU) rolls on, companies are showcasing more data in presentations. BioSpace takes a look at some of the latest.
Bayer's investigational drug darolutamide plus androgen deprivation therapy (ADT) significantly extends metastasis-free survival compared to placebo plus ADT in non-metastatic castration-resistant prostate cancer
First results from the Phase III ARAMIS trial with the investigational androgen receptor antagonist darolutamide were presented in an oral presentation at American Society of Clinical Oncology Genitourinary Cancers Symposium and simultaneously published in The New England Journal of Medicine
Program enables domestic violence shelters to offer on-site pet care so women aren't forced to choose between staying in a dangerous situation and leaving their pet behind
Bayer U.S. announced today that Raymond F. Kerins, Jr., Senior Vice President of Corporate Affairs, is the new Chairman of the U.S. Chamber of Commerce's Global Innovation Policy Center (GIPC).
Takeda Pharmaceutical released data from its Phase IIIb/IV clinical trial for Adynovate. On the same day, jurors in a Delaware federal court ordered Takeda’s Baxalta unit to pay $155.19 million to Bayer AG for infringing a patent for Adynovate.
First presentation of data from the pivotal Phase III ARAMIS trial with the investigational compound darolutamide in patients with non-metastatic castration-resistant prostate cancer
Tempting tubers get their good looks and heavy weights from healthy roots.
Safety and efficacy of Essure® have not changed
Program could lead to new crop protection solutions for farmers worldwide
An analysis shows that more than 30 drugmakers plan to increase the price of prescription medicine in January, despite presidential rhetoric.